{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T15:58:14Z","timestamp":1757779094112,"version":"3.40.4"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T00:00:00Z","timestamp":1612483200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Paget disease is a complex disorder that can be identified in the breast (mammary Paget disease) or in other locations (extramammary Paget's disease) such as ano-genital skin (Paget disease of the vulva -PVD). This condition is associated with low mortality, but a late diagnosis and recurrence can negatively impact the prognosis. Therefore, the main objective of this study is to evaluate if the human epididymis protein 4 (HE4) and cancer antigen125 (CA125) can promote recognition of PVD in early stages and during the relapses.<\/jats:p>\n            <jats:p>we have conducted a prospective, observational and laboratory-based study, that included 50 patients, whose 25 healthy women represented the control group and 25 PVD patients, which have been operated in our Oncology Institute, from May 2017 to September 2019. Both in the control group and in PVD patients, the CA-125 and HE4 were evaluated before surgery and after 6\u200amonths. Finally, a comparison of markers serum level, both between before\/after surgery and with control group, and a ROC (Receiver Operating Characteristic) curve were performed.<\/jats:p>\n            <jats:p>Dosing the markers in PVD patients, 3\/25 (12%) showed a higher value of CA125 and 11\/25 (44%) an increased HE4. In addition, after surgical treatment there were no statistically significant difference between levels of CA-125 (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.3) and HE4 (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.19). On the other hand, comparing HE4 in PVD patients with the control group, a statistically significant difference was found (<jats:italic toggle=\"yes\">P<\/jats:italic>-value = .0036). Contrary, comparing CA-125 in PVD patients with the control group (<jats:italic toggle=\"yes\">P<\/jats:italic>-value= .1969), no statistically significant difference was evidenced. Moreover, ROC (Receiver Operating Characteristic) curve showed low sensitivity and specificity for CA125 with area under curve (AUC) = 0.5608. Instead, the ROC curve of HE4 revealed a sensitivity and specificity of 76% and 88% respectively (AUC\u200a=\u200a0.7408) using a cut-off at 90\u200apmol\/L.<\/jats:p>\n            <jats:p>Despite the limited cases, our data showed that CA125 is not a sensitive marker for PVD. On the other hand, in 44% of PVD we\u2019ve seen an increase in HE4. So, this could be a starting point for further research that could confirm the possibility to use this marker in order to support PVD early identification.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000024485","type":"journal-article","created":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T19:41:29Z","timestamp":1614109289000},"page":"e24485","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":16,"title":["A strengthening the reporting of observational studies in epidemiology (STROBE)"],"prefix":"10.1097","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3522-4648","authenticated-orcid":false,"given":"Miriam","family":"Dellino","sequence":"first","affiliation":[{"name":"Gynecologic Oncology Unit, IRCCS Istituto Tumori \u201cGiovanni Paolo II\u201d Bari"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulio","family":"Gargano","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology Unit, IRCCS Istituto Tumori \u201cGiovanni Paolo II\u201d Bari"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffele","family":"Tinelli","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, \u201cValle d\u2019Itria\u201d Hospital, Martina Franca, Taranto"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmine","family":"Carriero","sequence":"additional","affiliation":[{"name":"Department Interdisciplinary Medicine, Unit of Obstetrics and Gynecology, University of Bari \u201cAldo Moro\u201d"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Minoia","sequence":"additional","affiliation":[{"name":"Haematology Unit, IRCCS Istituto Tumori \u201cGiovanni Paolo II\u201d Bari"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Skrypets","family":"Tetania","sequence":"additional","affiliation":[{"name":"Haematology Unit, National Cancer Center, IRCCS Istituto Tumori \u201cGiovanni Paolo II\u201d, viale O. Flacco 65, Bari, Italy; Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica","family":"Silvestris","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology Unit, IRCCS Istituto Tumori \u201cGiovanni Paolo II\u201d Bari"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vera","family":"Loizzi","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences and Human Oncology, Unit of Obstetrics and Gynaecology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Paradiso","sequence":"additional","affiliation":[{"name":"IRCCS Istituto Tumori \u201cGiovanni Paolo II\u201d"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Porzia","family":"Casamassima","sequence":"additional","affiliation":[{"name":"Clinical Patology Laboratory, IRCCS Istituto Tumori \u201cGiovanni Paolo II\u201d"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Tufaro","sequence":"additional","affiliation":[{"name":"Istitutional Biobank, IRCCS Istituto Tumori \u201cGiovanni Paolo II\u201d Bari, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gennaro","family":"Cormio","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences and Human Oncology, Unit of Obstetrics and Gynaecology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vito Michele","family":"Garrisi","sequence":"additional","affiliation":[{"name":"Clinical Patology Laboratory, IRCCS Istituto Tumori \u201cGiovanni Paolo II\u201d"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,2,5]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1158\/0008-5472.CAN-04-3924","article-title":"Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas","volume":"65","author":"Drapkin","year":"2005","journal-title":"Cancer Res"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/jcla.20340","article-title":"The utility of serum human epididymis protein 4 (HE4) in patients with a pelvic mass","volume":"23","author":"Montagnana","year":"2009","journal-title":"J Clin Lab Anal"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejogrb.2014.10.012","article-title":"Management of presumed benign ovarian tumors: updated French guidelines","volume":"183","author":"Brun","year":"2014","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/1096-9098(200012)75:4<264::AID-JSO7>3.0.CO;2-Q","article-title":"Benign conditions associated with raised serum CA-125 concentration","volume":"75","author":"Buamah","year":"2000","journal-title":"J Surg Oncol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000446238","article-title":"Is the risk of ovarian malignancy algorithm better than other tests for predicting ovarian malignancy in women with pelvic masses","volume":"82","author":"Yanaranop","year":"2017","journal-title":"Gynecol Obstet Invest"},{"key":"R6-20250504","first-page":"601","article-title":"Human epydidimis protein 4 (HE4): could it be useful in the diagnosis of vulvar cancer?","volume":"56","author":"Montagnana","year":"2010","journal-title":"Clin Lab"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/IGC.0000000000001189","article-title":"Extramammary paget disease of the vulva: a case series examining treatment, recurrence, and malignant transformation","volume":"28","author":"Nitecki","year":"2018","journal-title":"Int J Gynecol Cancer"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1097\/DAD.0000000000001311","article-title":"Extramammary Paget disease-A challenging case","volume":"41","author":"Yildiz","year":"2019","journal-title":"Am J Dermatopathol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.critrevonc.2016.03.008","article-title":"Paget disease of the vulva","volume":"101","author":"van der Linden","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1186\/s12885-018-4257-1","article-title":"Survival analysis of patients with invasive extramammary Paget disease: implications of anatomic sites","volume":"18","author":"Yao","year":"2018","journal-title":"BMC Cancer"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.hoc.2018.09.003","article-title":"Extramammary Paget's Disease","volume":"33","author":"Asel","year":"2019","journal-title":"Hematol Oncol Clin North Am"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ygyno.2012.07.106","article-title":"Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass","volume":"127","author":"Karlsen","year":"2012","journal-title":"Gynecol Oncol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"803598","DOI":"10.1155\/2014\/803598","article-title":"Borderline ovarian tumors and diagnostic dilemma of intraoperative diagnosis: could preoperative He4 assay and ROMA score assessment increase the frozen section accuracy? A multicenter case-control study","volume":"2014","author":"Gizzo","year":"2014","journal-title":"Biomed Res Int"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/ajo.12363","article-title":"HE4, CA125, the risk of malignancy algorithm and the risk of malignancy index and complex pelvic masses - a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population","volume":"55","author":"Richards","year":"2015","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"13030","DOI":"10.5070\/D3254043591","article-title":"Extramammary Paget disease","volume":"25","author":"St Claire","year":"2019","journal-title":"Dermatol Online J"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jdcr.2018.08.010","article-title":"An advanced case of extramammary Paget disease: Safe and effective treatment in an inoperable elderly patient using extensive en face electron irradiation","volume":"5","author":"Valle","year":"2018","journal-title":"JAAD Case Rep"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000507055","article-title":"The multifaceted nature of tumor microenvironment in breast carcinomas","volume":"87","author":"Annaratone","year":"2020","journal-title":"Pathobiology"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.jogc.2020.03.007","article-title":"Primary vaginal carcinoma arising on cystocele mimicking vulvar cancer","volume":"42","author":"Dellino","year":"2020","journal-title":"J Obstet Gynaecol Can"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"13030","DOI":"10.5070\/D32310037001","article-title":"Primary vulvar Paget disease - the importance of clinical suspicion","volume":"23","author":"Mota","year":"2017","journal-title":"Dermatol Online J"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1177\/1010428317730246","article-title":"Clinical performance of LOCI\u2122-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gnecological cancers","volume":"39","author":"Dolscheid-Pommerich","year":"2017","journal-title":"Tumour Biol"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"e17018","DOI":"10.1097\/MD.0000000000017018","article-title":"Paget disease of the vulva an analysis of 24 cases","volume":"98","author":"Loiacono","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/phpp.12386","article-title":"Complete response of extramammary Paget's disease with imiquimod and PDT: Report of two cases","volume":"34","author":"Apalla","year":"2018","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00432-020-03136-7","article-title":"Breast cancer: an update on treatment-related infertility","volume":"146","author":"Silvestris","year":"2020","journal-title":"J Cancer Res Clin Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000024485","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T06:15:00Z","timestamp":1746339300000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000024485"}},"subtitle":["Are HE4 and CA 125 suitable to detect a Paget disease of the vulva?"],"short-title":[],"issued":{"date-parts":[[2021,2,5]]},"references-count":23,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000024485","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2021,2,5]]},"assertion":[{"value":"2020-08-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}